share_log

Eupraxia Pharmaceuticals Brief: Announcing Data From RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

ユープラクシア製薬の概要:Eosinophilic Esophagitisの治療におけるEP-104GIのRESOLVE第1b/2a試験のデータの発表

MT Newswires ·  09/11 19:02

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする